IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
Herbst R, Kim E, Harari P. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion On Biological Therapy 2001, 1: 719-732. PMID: 11727507, DOI: 10.1517/14712598.1.4.719.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Anti-epidermal growth factor receptor monoclonal antibodyAnti-EGFR monoclonal antibodiesMonoclonal antibodiesLocoregional disease recurrenceImportant adverse eventsPhase I studiesReceptor monoclonal antibodyExcellent response ratesTreatment of headHuman tumor xenograftsExtracellular receptor sitesInhibition of metastasisEnhanced tumor invasionPotent antitumour activityAnticancer treatment strategiesGrowth factor receptorCancer cell linesAdverse eventsRefractory diseaseSkin rashWeekly infusionsDisease recurrence